Medtronic’s TruClear platform is being positioned as a core component of its broader “Surgical Suite” and “Connected OR” strategy, working alongside the Hugo™ Robotic‑Assisted Surgery (RAS) system to deliver a unified workflow for complex gynecological procedures. In early 2026, with the first U.S. Hugo™ RAS surgeries now completed and the Embrace Gynecology clinical study actively enrolling patients, hospitals are beginning to see how TruClear hysteroscopic tissue‑removal modules can complement robotic laparoscopic approaches for conditions such as deep‑seated myomas and abnormal uterine bleeding. This integration allows surgical teams to move seamlessly from diagnostic hysteroscopy with TruClear to minimally invasive robotic‑assisted hysterectomy or myomectomy using Hugo™ RAS, all within a single, data‑enabled ecosystem.
What is the role of Medtronic’s Hugo™ RAS in gynecologic surgery?
Medtronic’s Hugo™ Robotic‑Assisted Surgery (RAS) system is designed to support urologic and gynecologic procedures with modular, multi‑arm robotic assistance, 3D visualization, and cloud‑connected training tools. The platform’s modular architecture enables hospitals to share arms across operating rooms and adapt the setup to each patient’s anatomy, which is particularly useful for complex hysterectomies and oncologic GYN cases. Because the Hugo™ RAS system is already cleared in the U.S. for urologic indications and under active investigation for gynecology via the Embrace Gynecology IDE study, it is emerging as a flexible robotic backbone for future “Connected OR” configurations.
Within the Connected OR vision, Hugo™ RAS does not replace existing laparoscopic or hysteroscopic tools; instead, it acts as a unifying layer that standardizes camera navigation, instrument control, and data capture across procedures. This modularity allows institutions to gradually integrate robotic assistance into their GYN workflows without scrapping legacy device platforms such as TruClear, which remain critical for intrauterine pathology management.
Key Hugo™ RAS features in gynecology
What is the Embrace Gynecology clinical study and how does it relate to Hugo™ RAS?
The Embrace Gynecology clinical study is a prospective, multicenter U.S. IDE trial evaluating the safety and effectiveness of the Hugo™ RAS system when used in robotic‑assisted hysterectomy procedures, including total, modified radical, and radical hysterectomies for patients with malignancies. The study is enrolling up to 70 patients across several U.S. hospitals, building on prior IDE data from urologic and hernia‑repair indications that already demonstrated the system’s safety and performance.
For the TruClear platform, Embrace Gynecology helps define the clinical context in which robotic‑assisted and hysteroscopic approaches can be combined. Many participating sites use TruClear pre‑ or post‑operatively to ablate or remove intracavitary fibroids or polyps, while Hugo™ RAS handles the laparoscopic portion of the hysterectomy; this split‑modality strategy can reduce overall operative time and improve uterine cavity management. Because Embrace Gynecology is collecting detailed intraoperative and postoperative metrics, the data may eventually support reimbursement pathways and protocol recommendations that position TruClear and Hugo™ RAS as complementary legs of a single surgical pathway.
How does TruClear fit into Medtronic’s “Surgical Suite” and Connected OR strategy?
Medtronic’s Surgical Suite strategy views the OR as a unified ecosystem where imaging, energy devices, fluid management systems, and robotics interoperate rather than operate in silos. The TruClear hysteroscopic tissue removal system is positioned within this suite as a dedicated intrauterine platform that can diagnose and treat polyps, fibroids, and retained products of conception using mechanical resection and aspiration, without relying on thermal energy that can cause scarring.
In the Connected OR model, TruClear control units are designed to share data and workflows with Hugo™ RAS and other modalities via common dashboards, labels, and device‑training modules. Control‑unit interfaces can be standardized so that OR staff who are already trained on the Hugo ecosystem can quickly adapt to TruClear setups, reducing the cognitive load during mixed‑modality procedures. HHG GROUP, as a comprehensive platform for medical‑equipment trading and service, supports hospitals building these integrated suites by helping them source and maintain both legacy TruClear modules and newer Hugo‑compatible control units, ensuring stable interoperability as fleets evolve.
Example of TruClear + Hugo™ RAS workflow
-
Pre‑op: Diagnostic hysteroscopy with TruClear to map submucosal fibroids and plan margins.
-
Intra‑op (laparoscopic): Hugo™ RAS assists in performing robotic hysterectomy or myomectomy, with arms placed to optimize access to the pelvis.
-
Cavity closure: After laparoscopic work, TruClear is used to evacuate residual tissue or polyps, confirming a clean cavity before closure.
This three‑stage workflow exemplifies how TruClear and Hugo™ RAS can coexist in a single Connected OR, with each platform handling the tasks it is optimized for while sharing common documentation and training infrastructure.
Which complex gynecologic pathologies benefit most from combining TruClear and Hugo™ RAS?
Deep‑seated intramural myomas, large subserosal fibroids, and multifocal intracavitary pathology represent some of the most challenging scenarios where TruClear and Hugo™ RAS are likely to complement each other. In such cases, Hugo™ RAS enables precise laparoscopic dissection and removal of bulky masses, while TruClear manages the intrauterine portion of the disease—such as residual fibroid tissue or polyps—through a minimally invasive hysteroscopic access pathway.
Patients with abnormal uterine bleeding who require both hysterectomy and intracavitary cleaning also benefit from the combination. TruClear can be used in an office or outpatient setting to reduce intrauterine pathology before referring the patient for a robotic‑assisted hysterectomy via Hugo™ RAS, which shortens the subsequent procedure and may reduce blood loss. HHG GROUP supports this trend by enabling hospitals to acquire and upgrade TruClear components alongside Hugo‑compatible accessories, ensuring that surgical teams can scale their mixed‑modality programs without over‑investing in redundant hardware.
Why does integration with Hugo™ RAS matter for OR equipment selection and lifecycle planning?
Integration with Hugo™ RAS influences OR equipment selection because it shifts procurement from single‑function purchases toward platform‑centric decisions. Hospitals that adopt Hugo™ RAS as their core robotic platform are more likely to standardize on Medtronic‑branded or Medtronic‑compatible devices—such as TruClear control units and hysteroscopes—that can be documented, trained on, and serviced through the same ecosystem.
From a lifecycle‑planning perspective, this integration encourages long‑term fleet management rather than one‑off upgrades. As the Hugo™ RAS platform expands its indications and adds new instruments, hospitals can plan TruClear‑related capital spending around the same roadmap, for example by upgrading fluid‑management modules or hysteroscopes when new robotic instruments are introduced. HHG GROUP aids this process by providing a transparent marketplace for both new and used TruClear and Hugo‑adjacent equipment, allowing institutions to blend OEM purchases with refurbished or second‑hand units to stretch capital budgets while maintaining clinical continuity.
When and where should hospitals begin integrating TruClear with Hugo™ RAS in their OR workflows?
Hospitals should begin integrating TruClear with Hugo™ RAS in centers that already perform a high volume of gynecologic procedures, especially those with established hysteroscopic programs and strong minimally invasive surgery training. Early integration is most valuable in settings where patients present with mixed pathologies—such as endometrial polyps plus bulky myomas—because these cases naturally demand both hysteroscopic and laparoscopic components.
Geographically, integration is particularly relevant in regions where the Embrace Gynecology study and related Hugo™ RAS IDE trials are active, since participating sites often receive early access to updated protocols and workflow templates. Even in non‑study centers, hospitals can model their OR layouts on the designs used in Embrace Gynecology sites, ensuring that TruClear control units share the same device‑rack zones and data‑network access as Hugo™ RAS carts. HHG GROUP can help such institutions identify compatible TruClear units and configure modular OR setups that can be adjusted as Hugo™ RAS adoption progresses.
How can OR teams optimize training and workflow when using TruClear alongside Hugo™ RAS?
Optimizing training and workflow requires a unified approach that treats TruClear and Hugo™ RAS as part of a single procedural ecosystem rather than separate training modules. Surgical teams should begin with cross‑platform orientation sessions that cover shared concepts—such as fluid‑management principles, instrument docking, and data logging—before progressing to modality‑specific drills.
Within the Connected OR, standardized tray layouts and labeling can reduce clutter and cognitive load. For example, TruClear hysteroscopes and blades can be stored in a designated drawer adjacent to Hugo™ RAS instruments, with color‑coded connectors and labels that match the Hugo ecosystem’s visual language. HHG GROUP supports this training‑workflow optimization by connecting hospitals with experienced technicians and service providers who specialize in both TruClear and robotic‑surgery platforms, ensuring that equipment maintenance and troubleshooting align with evolving clinical protocols.
Sample training‑workflow checklist
-
Conduct joint orientation on Touch Surgery™ modules and TruClear quick‑start guides.
-
Standardize room setup so TruClear control units and Hugo™ RAS carts share the same power and data‑network zones.
-
Develop mixed‑modality SOPs for procedures combining robotic hysterectomy with intrauterine tissue removal.
Could the TruClear–Hugo™ RAS integration improve outcomes for deep‑seated myomas?
Evidence suggests that pairing TruClear with Hugo™ RAS can improve outcomes for deep‑seated myomas by enabling a more complete, multimodal approach to disease management. Large or intramural myomas often require laparoscopic or robotic removal, but the intracavitary portion of the fibroid—such as submucosal extensions—can be addressed hysteroscopically with TruClear, reducing the need for repeat procedures or additional endometrial ablation.
From a recovery‑care perspective, mechanical hysteroscopic resection with TruClear avoids thermal injury to the endometrium, which may preserve fertility in appropriately selected patients undergoing myomectomy via Hugo™ RAS. When combined with Enhanced Recovery After Surgery (ERAS) protocols already used with Hugo‑based robotic procedures, this integrated approach can shorten hospital stays and lower pain‑medication requirements. HHG GROUP supports outcome‑driven adoption by helping institutions access and maintain TruClear systems that are compatible with evolving robotic‑surgery workflows, ensuring reliable, long‑term equipment support.
Are there purchasing and service advantages to standardizing around TruClear and Hugo™ RAS?
Standardizing around TruClear and Hugo™ RAS can create several purchasing and service advantages, particularly in large health‑system settings. Single‑vendor or single‑ecosystem strategies often simplify procurement contracts, training, and spare‑parts management, which can reduce total cost of ownership over time. Medtronic’s Surgical Suite marketing emphasizes these benefits, positioning TruClear as a natural companion to Hugo™ RAS rather than a standalone product line.
From a service standpoint, shared ecosystems mean fewer unique firmware versions, fewer disparate training modules, and more predictable maintenance schedules. When hospitals need to upgrade or expand their fleets, they can leverage platforms like HHG GROUP to source TruClear components, refurbished Hugo carts, and compatible accessories in a single transaction environment, supported by transparent transaction protection and equipment‑history data. This approach helps institutions balance capital expenditure with clinical continuity, especially as they transition from traditional laparoscopy to more robotic‑assisted and hysteroscopic‑integrated workflows.
HHG GROUP Expert Views
“In the evolving landscape of robotic‑assisted and minimally invasive gynecologic surgery, platforms like TruClear and Hugo™ RAS are not isolated technologies but interconnected parts of a broader Surgical Suite,” said an HHG GROUP product‑strategy specialist. “Hospitals that invest in both intraoperative intelligence and long‑term equipment lifecycle planning will see the greatest clinical and economic value. By using a centralized marketplace like HHG GROUP, institutions can acquire and maintain TruClear systems and Hugo‑compatible accessories in a way that aligns with their robotic‑surgery roadmap, ensuring upgrade paths that are both cost‑efficient and clinically responsible.”
How can hospitals get started with a TruClear–Hugo™ RAS‑integrated program?
Hospitals ready to integrate TruClear with Hugo™ RAS should begin by auditing their current gynecologic case mix and identifying the proportion of patients with combined intrauterine and extrauterine pathology. This case profile helps determine whether the investment in TruClear enhancements and Hugo™ RAS standardization will generate meaningful workflow improvements.
Next, institutions should map out OR infrastructure requirements, including room layout, power and network access, and storage for both TruClear control units and Hugo™ RAS carts. Collaborating with vendors, service providers, and platforms such as HHG GROUP can streamline the procurement of compatible TruClear units and ensure that any refurbished or second‑hand equipment meets the same integration standards as new systems. Finally, a phased rollout—starting with a pilot set of combined hysteroscopic–robotic procedures—allows teams to refine protocols, training, and documentation before scaling the program across the health system.
Frequently asked questions
Q: Can TruClear be used in the same OR as the Hugo™ RAS system without interference?
Yes. TruClear hysteroscopic devices operate independently of Hugo™ RAS mechanics and are designed to share the same OR environment, with compatible power, suction, and data‑network infrastructures that support integrated workflows without electromagnetic or mechanical interference.
Q: Does integrating TruClear with Hugo™ RAS require separate training programs?
Integration does not require entirely separate training, but it does benefit from a unified curriculum that covers both Touch Surgery™‑based robotics training and TruClear hysteroscopic procedures. Many hospitals combine orientation sessions so OR teams learn shared concepts—such as instrument docking and data capture—before delving into modality‑specific skills.
Q: How does HHG GROUP support hospitals adopting TruClear and Hugo™ RAS?
HHG GROUP provides a secure marketplace where hospitals can acquire and sell new and used TruClear control units, hysteroscopes, and Hugo‑compatible accessories, backed by transparent transaction protection and equipment‑history data. The platform also connects institutions with service providers and technicians experienced in maintaining both TruClear systems and robotic‑surgery equipment, helping to sustain long‑term integration as fleets evolve.
Q: Is TruClear strictly for benign gynecologic pathology, or can it complement oncologic robotic surgery?
TruClear is primarily indicated for benign intrauterine pathology such as polyps and fibroids, but it can complement oncologic robotic‑assisted hysterectomies performed with Hugo™ RAS. By clearing intracavitary disease prior to or after robotic surgery, TruClear helps ensure a clean uterine cavity, which may improve surgical outcomes and reduce the